{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:40:57Z","timestamp":1760042457737,"version":"3.40.4"},"reference-count":82,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6641,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:p>Overt proteinuria is often accompanied by hypercholesterolemia and is associated with increased lipoprotein(a) levels. These lipid abnormalities are probably involved in the high incidence of macrovascular complications associated with diabetic nephropathy and possibly other kinds of non\u2010diabetic proteinuric renal disease. Over the last decade many studies have shown that ACE inhibitors can reduce urinary protein excretion but little attention was paid to the impact of this form of therapeutic intervention on the lipid profile. In this article we review our recent data showing that fosinopril administration was associated with significant decreases in both urinary protein excretion, serum total cholesterol levels, and plasma lp(a) levels. The use of ACE inhibitors in patients with renal impairment can result in the development of hyperkalemia as a result of suppression of angiotensin II\u2010driven aldosterone secretion by the adrenal gland. Inhibition of aldosterone secretion may depend on the degree of inhibition of angiotensin II formation in the circulation and also locally in the adrenal gland. Because the various ACE inhibitors exhibit different degrees of ACE inhibition at the tissue level, we have postulated that angiotensin II\u2010dependent aldosterone production will be inhibited to a lesser degree by agents that have low tissue affinity for the adrenal gland. The implication of this theoretical concept for the development of hyperkalemia in patients with impaired renal function treated with ACE inhibitors is discussed.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1995.tb04750.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:04:26Z","timestamp":1362769466000},"page":"87-97","source":"Crossref","is-referenced-by-count":13,"title":["Selected Aspects of ACE Inhibitor Therapy for Patients with Renal Disease: Impact on Proteinuria, Lipids and Potassium"],"prefix":"10.1002","volume":"35","author":[{"given":"Taha","family":"Keilani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Schlueter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Batlle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6823.339"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.294.6585.1448"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-8-199304150-00001"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80116-8"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70256-1"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00002"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00002"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512263132601"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.190"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6545.471"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.39.1.76"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90584-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-9-707"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6729.904"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.173"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80483-5"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80288-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198812040-00147"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80696-2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.193"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.284"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.57"},{"issue":"22","key":"e_1_2_1_25_2","first-page":"S49","article-title":"Factors affecting progression of renal failure in patients on long\u2010term dietary protein restriction","volume":"32","author":"Maschio G","year":"1983","journal-title":"Kidney Int"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1986.88"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000183130"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92450-3"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198407123110204"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.294.6585.1448"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90231-5"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008303230905"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008303230910"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.51"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91513-6"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.87"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114750"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506133122404"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104277"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00282175"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00293891"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114625"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480080079031"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.10.2.240"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(90)90177-K"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/clinchem\/33.5.721","article-title":"Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis","volume":"33","author":"Parra JH","year":"1987","journal-title":"Clin Chem"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.74.4.758"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2337\/diab.40.6.787","article-title":"Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria","volume":"40","author":"Jenkins AJ","year":"1991","journal-title":"Diabetes"},{"issue":"24","key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1001\/jama.1992.03480240088040","article-title":"Lipoprotein(a). A genetic risk factor for premature coronary heart disease","volume":"267","author":"Scanu AM","year":"1992","journal-title":"JAMA"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02190527"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.63"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8503012"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6804.675"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(88)90034-2"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.5.1313"},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/clinchem\/35.10.2121","article-title":"Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin","volume":"35","author":"Karadi I","year":"1989","journal-title":"Clin Chem"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.5.3.265"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)91053-K"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90415-6"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.1.3.274"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1982.14"},{"key":"e_1_2_1_62_2","first-page":"49","volume-title":"The Principles and Practice of Nephrology","author":"Rombola G","year":"1991"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80110-7"},{"key":"e_1_2_1_64_2","first-page":"503","article-title":"Adrenal renin: a possible local hormonal regulator of aldosterone production","volume":"62","author":"Mulrow PJ","year":"1989","journal-title":"Yale J Biol Med"},{"issue":"1","key":"e_1_2_1_65_2","first-page":"S81","article-title":"Tissue renin angiotensin systems: Theoretical implications for the development of hyperkalemia using angiotensin\u2010converting enzyme inhibitors","volume":"307","author":"Schlueter W","year":"1994","journal-title":"Am J Med Sci"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.6.2_Pt_2.I124"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.10.3295"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-1-486"},{"key":"e_1_2_1_69_2","first-page":"319","article-title":"In vitro evidence for local generation of renin and angiotensin II\/III immunoreactivity by the human adrenal gland","volume":"125","author":"Fallo F","year":"1991","journal-title":"Acta Endocrinol"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6198.1106"},{"issue":"1","key":"e_1_2_1_71_2","first-page":"109","article-title":"Enalapril (MK421) in the treatment of hypertension with renal artery stenosis","volume":"1","author":"Hodsman GP","year":"1983","journal-title":"J Hypertens"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198211000-00014"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90390-3"},{"key":"e_1_2_1_74_2","first-page":"281","article-title":"Converting enzyme inhibition with fosinopril does not suppress plasma aldosterone and may not cause hyperkalemia despite moderate renal impairment","volume":"2","author":"Keilani T","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/2.4.294"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199111000-00012"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.4.492"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641968709164213"},{"key":"e_1_2_1_79_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3565(25)32897-1","article-title":"Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK 421","volume":"220","author":"Cohen ML","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"e_1_2_1_80_2","first-page":"222A","article-title":"Therapeutic advantage of low dose angiotensin converting enzyme inhibition for patients with proteinuria and renal impairment","volume":"42","author":"Keilani T","year":"1994","journal-title":"Clin Res"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90629-2"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.11.3.230"},{"issue":"10","key":"e_1_2_1_83_2","first-page":"S75","article-title":"Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors","volume":"8","author":"Unger T","year":"1982","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1995.tb04750.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1995.tb04750.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:39:13Z","timestamp":1745969953000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1995.tb04750.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1002\/j.1552-4604.1995.tb04750.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04750.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}